Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy

Overview of attention for article published in Ophthalmology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 17 news outlets
twitter: 8 X users

patent: 1 patent

Readers on

mendeley: 72 Mendeley

So far, Altmetric has seen 19 news stories from 17 outlets.

Lineage Cell Therapeutics' Cellular Treatment For Dry Age-Related Macular Degeneration

Seeking Alpha, 11 Jan 2023

Follow Summary Lineage Cell Therapeutics' cellular treatment for dry age-related macular degeneration has been very successful…

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

BioSpace, 10 Mar 2021

Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an…

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

FirstWord Pharma, 10 Mar 2021

Data published in Ophthalmology and the underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for…

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

Jotup, 10 Mar 2021

The analysis, Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 15 additional news stories.